190 related articles for article (PubMed ID: 20860650)
1. Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention?
Coen JJ; Feldman AS; Smith MR; Zietman AL
BJU Int; 2011 May; 107(10):1582-6. PubMed ID: 20860650
[TBL] [Abstract][Full Text] [Related]
2. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
Choo R; Klotz L; Danjoux C; Morton GC; DeBoer G; Szumacher E; Fleshner N; Bunting P; Hruby G
J Urol; 2002 Apr; 167(4):1664-9. PubMed ID: 11912384
[TBL] [Abstract][Full Text] [Related]
3. Active surveillance strategy for patients with localised prostate cancer: criteria for progression.
Thomsen FB
Dan Med J; 2015 Feb; 62(2):. PubMed ID: 25634510
[TBL] [Abstract][Full Text] [Related]
4. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
[TBL] [Abstract][Full Text] [Related]
5. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
6. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.
Margel D; Nandy I; Wilson TH; Castro R; Fleshner N
J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059
[TBL] [Abstract][Full Text] [Related]
7. Population-based study of grade progression in patients who harboured Gleason 3 + 3.
Sampurno F; Earnest A; Millar J; Frydenberg M; Murphy D; Delprado W; Evans S
World J Urol; 2017 Nov; 35(11):1689-1699. PubMed ID: 28500489
[TBL] [Abstract][Full Text] [Related]
8. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
9. Medium-term outcomes of active surveillance for localised prostate cancer.
Selvadurai ED; Singhera M; Thomas K; Mohammed K; Woode-Amissah R; Horwich A; Huddart RA; Dearnaley DP; Parker CC
Eur Urol; 2013 Dec; 64(6):981-7. PubMed ID: 23473579
[TBL] [Abstract][Full Text] [Related]
10. A single-center long-term experience of active surveillance for prostate cancer: 15 years of follow-up.
Song SH; Kim JK; Lee H; Lee S; Hong SK; Byun SS
Investig Clin Urol; 2021 Jan; 62(1):32-38. PubMed ID: 33258324
[TBL] [Abstract][Full Text] [Related]
11. Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma.
McLaren DB; McKenzie M; Duncan G; Pickles T
Cancer; 1998 Jan; 82(2):342-8. PubMed ID: 9445192
[TBL] [Abstract][Full Text] [Related]
12. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
13. PSA doubling time of prostate carcinoma managed with watchful observation alone.
Choo R; DeBoer G; Klotz L; Danjoux C; Morton GC; Rakovitch E; Fleshner N; Bunting P; Kapusta L; Hruby G
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):615-20. PubMed ID: 11395227
[TBL] [Abstract][Full Text] [Related]
14. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
15. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies.
Cary KC; Cowan JE; Sanford M; Shinohara K; Perez N; Chan JM; Meng MV; Carroll PR
Eur Urol; 2014 Aug; 66(2):337-42. PubMed ID: 24035632
[TBL] [Abstract][Full Text] [Related]
16. An evidence review of active surveillance in men with localized prostate cancer.
Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
[TBL] [Abstract][Full Text] [Related]
17. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
[TBL] [Abstract][Full Text] [Related]
18. Active surveillance for low-risk prostate cancer: Need for intervention and survival at 10 years.
Preston MA; Feldman AS; Coen JJ; McDougal WS; Smith MR; Paly JJ; Carrasquillo R; Wu CL; Dahl DM; Barrisford GW; Blute ML; Zietman AI
Urol Oncol; 2015 Sep; 33(9):383.e9-16. PubMed ID: 26059076
[TBL] [Abstract][Full Text] [Related]
19. Early outcomes of active surveillance for localized prostate cancer.
Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of nonpalpable prostate cancer with favorable biopsy features in Japanese men.
Kakehi Y; Kamoto T; Ogawa O; Kato T; Tobisu K; Akakura K; Egawa S; Usami M; Maeda O; Arai Y; Sumiyoshi Y; Kamiryo Y; Yoshida O
Eur Urol; 2000 May; 37(5):552-8. PubMed ID: 10765093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
